As the ink dries on the US approval of Novartis' heart failure treatment Entresto, talk has quickly shifted to pricing issues, and possible outcomes-based plans, rather than the drug's very ...

consider alternatives and discontinue Entresto. However, if there is no appropriate alternative therapy with drugs affecting the renin-angiotensin system, and if the drug is considered lifesaving ...

The launch of a generic version of Novartis's (NYSE:NVS) blockbuster cardiac drug Entresto has reportedly been temporarily ...

A three-judge panel wrestled Thursday with Novartis AG’s challenge against the FDA over its approval of a generic version of ...

The Federal Circuit reversed finding sufficient written description. The Federal Circuit explained that the written description requirement pertains only to the claims themselves and the construction ...

Novartis’ Entresto is on course to become the first drug to be approved in the US for a form of heart failure that is notoriously hard to treat effectively, despite missing the mark in a phase 3 ...

A recent federal court decision highlights the delicate balance between U.S. Food and Drug Administration (FDA) guidance and trade dress ...

These growth drivers should offset exclusivity losses on cardiovascular drug Entresto, cancer drug Tasigna, and blood treatment Promacta over the next five years. In the pipeline, Novartis is ...